Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF) today announced its financial and operational results for the three months ended September 30, 2012 ("Q3 2012"). Q3 2012 Summary Achieved...

Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF) today announced it will host a conference call for its Q3 2012 financial results on Wednesday, October 24, 2012 at 8:30AM ET. Q3 2012 CONFERENCE CALL

Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at the Rodman & Renshaw 14th Annual Healthcare...

- In-license agreement for the Betesil® Patch to treat inflammatory skin conditions - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Aug. 7, 2012 /CNW/ - Cipher Pharmaceuticals Inc., (TSX:...

- Results highlighted by solid revenue growth and FDA approval of CIP-ISOTRETINOIN - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, July 25, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:...

Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF) today announced it will host a conference call for its Q2 2012 financial results on Wednesday, July 25, 2012. Q2 2012 CONFERENCE CALL WHEN:...

Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at the Bloom & Burton Healthcare Investor Conference,...

Product to be launched as Absorica™ Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 27, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) announced today that the U.S....

Product to be launched as Absorica™ Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 27, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) announced today that the U.S....

Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) today announced its financial and operational results for the three months ended March 31, 2012 ("Q1 2012"). Q1 2012 Summary Achieved...

Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) today announced it will host a conference call for its Q1 2012 financial results and hold its Annual Meeting of Shareholders on Friday, May 4,...

Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) today announced that its partner, Medical Futures Inc. ("Medical Futures"), has launched Durela™ (extended-release tramadol) in Canada. The...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the fourth quarter and fiscal year ended December 31, 2011. Fiscal 2011 Summary Completed...

- Financial results to be released February 22, 2012 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Feb. 15, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) will host a conference call...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it reached a sales milestone for Lipofen®, the Company's fenofibrate product. This one-time milestone, which is based on sales...

Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that its New Drug Submission for CIP-ISOTRETINOIN, a novel, patented formulation of the acne medication...

Toronto Stock Exchange Symbol: DND - Company receives US$1.0 million milestone - - Company also files New Drug Submission with Health Canada - MISSISSAUGA, ON, Dec. 21, 2011 /CNW/ - Cipher...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has submitted an amendment to its pending New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three months ended September 30, 2011 ("Q3 2011"). Q3 2011 Summary Cipher's U.S. marketing...

- Third quarter financial results to be released October 26, 2011 - Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 19, 2011 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a...

Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that it has entered into a distribution and supply agreement with Medical Futures Inc. ("Medical Futures"), a...

Cipher Pharmaceuticals Inc. (TSX: DND), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at the Rodman & Renshaw Annual Global Investment Conference, which...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced that Health Canada has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately...

Cipher Pharmaceuticals Inc. (TSX: DND) today announced its financial and operational results for the three and six months ended June 30, 2011 ("Q2 2011"). Q2 2011 Summary Licensed the U.S....

- Second quarter financial results to be released July 26, 2011 - Toronto Stock Exchange Symbol: DND MISSISSAUGA,ON, July 7, 2011 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a...